Jade Biosciences, Inc. Common Stock JBIO Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $93.12M+43.3% | $64.97M+1.2% | $64.22M+66.3% | $38.62M+158% | ||
| $20.42M+90.2% | $10.74M-37.5% | $17.19M+17.6% | $14.62M+81.9% | ||
| $113.54M+50.0% | $75.71M-7.0% | $81.41M+52.9% | $53.24M+131% | ||
| -$113.54M-50.0% | -$75.71M+7.0% | -$81.41M-52.9% | -$53.24M-131% | ||
| —— | -$11.32M-290% | $5.94M+239% | $1.75M+2,726% | ||
| —— | —— | -$75.47M— | —— | ||
| $58K— | —— | $56K+124% | $25K+733% | ||
| -$127.41M-46.4% | -$87.03M-15.2% | -$75.52M-46.6% | -$51.51M-124% | ||
| -$13.55+35.7% | -$21.07-632% | -$2.88-36.5% | -$2.11— | ||
| -$113.52M-50.5% | -$75.43M+7.2% | -$81.31M-52.9% | -$53.17M-131% | ||
| -$113.54M-50.0% | -$75.71M+7.0% | -$81.41M-52.9% | -$53.24M-131% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Jade Biosciences, Inc. Common Stock profitable?
- Jade Biosciences, Inc. Common Stock is not currently profitable: it reported a net loss of $129.6M over the trailing twelve months.
- What is Jade Biosciences, Inc. Common Stock's earnings per share?
- Jade Biosciences, Inc. Common Stock's diluted EPS over the trailing twelve months is $-2.02.
- Where does Jade Biosciences, Inc. Common Stock's income statement data come from?
- Every line is extracted from Jade Biosciences, Inc. Common Stock's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.